Antiepileptics (Anticonvulsants)

  • Eileen P. G. Vining
  • Richard O. Carpenter
  • Michael G. Aman


Child mental health professionals should be interested in anticonvulsant drugs for three reasons. First, epilepsy is a relatively common disorder in children and adolescents with developmental disabilities and behavioral disorders. Second, anticonvulsant drugs, acting as they do to alter brain excitability, often have effects on behavior, emotions, and cognition. Third, the psychotropic effects of certain anticonvulsants, notably carbamazepine, valproate, and clonazepam, now are utilized in the treatment of certain psychiatric disorders such as bipolar and anxiety disorders, and this psychiatric use may well extend further in the future.


Valproic Acid Antiepileptic Drug Partial Seizure Seizure Control Febrile Seizure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Freeman JM, Vining EPG, Pillas DJ: Seizures and Epilepsy in Childhood: A Guide for Parents. Baltimore, Johns Hopkins University Press, 1990.Google Scholar
  2. 2.
    Hauser WA, Hesdorffer DC: The natural history of seizures, in Wyllie E (ed): The Treatment of Epilepsy: Principles and Practice, ed 2. Baltimore, Williams & Wilkins, 1996, pp 173–178.Google Scholar
  3. 3.
    Hauser WA: Should people be treated after a first seizure? Arch Neurol 43:1287–1288, 1986.PubMedCrossRefGoogle Scholar
  4. 4.
    Hart RG, Easton JD: Seizure recurrence after a first, unprovoked seizure. Arch Neurol 43:1289–1298, 1986.PubMedCrossRefGoogle Scholar
  5. 5.
    Shinnar S, Berg AT, Moshe SL, et al: Risk of seizure recurrence following a first unprovoked seizure in childhood: A prospective study. Pediatrics 85:1076–1085, 1990.PubMedGoogle Scholar
  6. 6.
    Camfield CS, Camfield PR: General principles of antiepileptic drug therapy, in Wyllie E (ed): The Treatment of Epilepsy: Principles and Practice, ed 2. Baltimore, Williams & Wilkins, 1996, pp 763–770.Google Scholar
  7. 7.
    Shinnar S, Vining EPG, Mellits ED, et al: Discontinuing anticonvulsants in children with epilepsy after two years without seizures: A prospective study. N Engl J Med 313:976–980, 1985.PubMedCrossRefGoogle Scholar
  8. 8.
    Nelson KB, Ellenberg JH: Prognosis in children with febrile seizures. Pediatrics 61:720–727, 1978.PubMedGoogle Scholar
  9. 9.
    French JA: Antiepileptic drug development and experimental models, in Wyllie E (ed): The Treatment of Epilepsy: Principles and Practice, ed 2. Baltimore, Williams & Wilkins, 1996, pp 693–699.Google Scholar
  10. 10.
    Rall TW, Schleifer LS: Drugs effective in the therapy of the epilepsies, in Goodman AG, Rail TW, Nies AS, et al (eds): Goodman and Gilman’s The Pharmacological Basis of Therapeutics, ed 8. New York, Pergamon Press, 1990, pp 436–462.Google Scholar
  11. 11.
    Wyllie E (ed): The Treatment of Epilepsy: Principles and Practice, ed 2. Baltimore, Williams & Wilkins, 1996.Google Scholar
  12. 12.
    Engel J Jr, Pedley TA (eds): Epilepsy: A Comprehensive Textbook. Philadelphia, Lippincott-Raven, 1998.Google Scholar
  13. 13.
    Faingold CL, Fromm GH: Drugs for Control of Epilepsy: Actions on Neuronal Networks Involved in Seizure Disorders. Boca Raton, Fla, CRC Press, 1992.Google Scholar
  14. 14.
    Alvarez N, Kern RA, Cain NN, et al: Antiepileptics, in Reiss S, Aman MG (eds): Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook. Columbus Ohio, The Nisonger Center UAP, 1998.Google Scholar
  15. 15.
    Browne TR, Pincus JH: Phenytoin (Dilantin) and other hydantoins, in Browne TR, Feldman RG (eds): Epilepsy: Diagnosis and Management. Boston, Little, Brown & Co, 1983, pp 175–189.Google Scholar
  16. 16.
    Fraught E: Felbamate, in Wyllie E (ed): The Treatment of Epilepsy: Principles and Practice, ed 2. Baltimore, Williams & Wilkins, 1996, pp 913–919.Google Scholar
  17. 17.
    Messenheimer J: Lamotrigine, in Wyllie E (ed): The Treatment of Epilepsy: Principles and Practice, ed 2. Baltimore, Williams & Wilkins, 1996, pp 899–905.Google Scholar
  18. 18.
    Fisher R: Newer antiepileptic drugs, in Wyllie E (ed): The Treatment of Epilepsy: Principles and Practice, ed 2. Baltimore, Williams & Wilkins, 1996, pp 920–930.Google Scholar
  19. 19.
    Gowers WR: Epilepsy and Other Chronic Convulsive Diseases: Their Causes, Symptoms and Treatment. London, William Wood, 1885.Google Scholar
  20. 20.
    Lesser RP, Luders H, Wyllie E, et al: Mental deterioration in epilepsy. Epilepsia 27:S105-S123, 1986.CrossRefGoogle Scholar
  21. 21.
    Rutter M, Graham P, Yule W: A Neuropsychiatric Study in Childhood. London, Spastics International Medical Publications, 1970.Google Scholar
  22. 22.
    Farwell JR, Dodrill CB, Batzel LW: Neuropsychological abilities of children with epilepsy. Epilepsia 26:395–400, 1985.PubMedCrossRefGoogle Scholar
  23. 23.
    Henriksen O: Specific problems of children with epilepsy. Epilepsia 29:S6-S9, 1988.CrossRefGoogle Scholar
  24. 24.
    Smith DB, Mattson RH, Cramer JA, et al: Results of a nationwide Veterans Administration cooperative study comparing the efficacy and toxicity of carbamazepine, phenobarbital, phenytoin, and primidone. Epilepsia 28:S50-S58, 1987.CrossRefGoogle Scholar
  25. 25.
    Devinsky O: Cognitive and behavioral effects of antiepileptic drugs. Epilepsia 36(Suppl. 2):S46-S65, 1995.CrossRefGoogle Scholar
  26. 26.
    Dodrill CB, Troupin AS: Psychotropic effects of carbamazepine in epilepsy: A double blind comparison with phenytoin. Neurology 27:1023–1028, 1977.PubMedCrossRefGoogle Scholar
  27. 27.
    Dodrill CB, Troupin AS: Neuropsychological effects of carbamazepine and phenytoin: A reanalysis. Neurology 41:141–143, 1991.PubMedCrossRefGoogle Scholar
  28. 28.
    Schain RJ, Ward JW, Guthrie D: Carbamazepine as an anticonvulsant in children. Neurology 27:476–480, 1977.PubMedCrossRefGoogle Scholar
  29. 29.
    Trimble MR, Thompson PJ: Anticonvulsant drugs, cognitive function, and behavior. Epilepsia 24:S55-S63, 1983.CrossRefGoogle Scholar
  30. 30.
    Vining EPG, Mellits ED, Dorsen MM, et al: Psychologic and behavioral effects of antiepileptic drugs in children: A double blind comparison between phenobarbital and valproic acid. Pediatrics 80:165–174, 1987.PubMedGoogle Scholar
  31. 31.
    Committee on Drugs: Behavioral and cognitive effects of anticonvulsant therapy. Pediatrics 76:644–647, 1985.Google Scholar
  32. 32.
    Committee on Drugs: Behavioral and cognitive effects of anticonvulsant therapy. Pediatrics 96:538–540, 1995.Google Scholar
  33. 33.
    Herranz H, Armijo JA, Arteaga R: Clinical side effects of phenobarbital, primidone, phenytoin, carbamazepine, and valproate during monotherapy in children. Epilepsia 29:794–804, 1988.PubMedCrossRefGoogle Scholar
  34. 34.
    Camfield CS, Chaplin S, Doyle A, et al: Side effects of phenobarbital in toddlers: Behavioral and cognitive aspects. J Pediatr 95:361–365, 1979.PubMedCrossRefGoogle Scholar
  35. 35.
    Farwell JR, Lee YJ, Hirtz DG, et al: Phenobarbital for febrile seizures: Effects on intelligence and on seizure recurrence. N Engl J Med 322:364–369, 1990.PubMedCrossRefGoogle Scholar
  36. 36.
    Brent DA, Crumrine PK, Varma RR, et al: Phenobarbital treatment and major depressive disorder in children with epilepsy. Pediatrics 80:909–917, 1987.PubMedGoogle Scholar
  37. 37.
    Brent DA, Crumrine PK, Varma R, et al: Phenobarbital treatment and major depressive disorder in children with epilepsy: A naturalistic follow-up. Pediatrics 85:1086–1091, 1990.PubMedGoogle Scholar
  38. 38.
    Chen YJ, Kang WM, So WCM. Comparison of antiepileptic drugs on cognitive function in newly diagnosed epileptic children: A psychometric and neurophysiological study. Epilepsia 37:81–86, 1996.PubMedCrossRefGoogle Scholar
  39. 39.
    Vallarta JM, Bell DB, Reichert A: Progressive encephalopathy due to chronic hydantoin intoxication. Am J Dis Child 128:27–34, 1974.PubMedGoogle Scholar
  40. 40.
    Logan WJ, Freeman JM: Pseudodegenerative disease due to diphenylhydantoin intoxication. Arch Neurol 21:631–637, 1969.PubMedCrossRefGoogle Scholar
  41. 41.
    Trimble M, Corbett J: Anticonvulsant drugs and cognitive function, in Wada JA, Penry JK (eds): Advances in Epileptology: The Xth Epilepsy International Symposium. New York, Raven Press, 1980, pp 113–120.Google Scholar
  42. 42.
    Nolte R, Wetzel B, Brugmann G, et al: Effects of phenytoin and primidone monotherapy on mental performance in children, in Johannessen SI, Morselli PL, Pippenger CE, et al (eds): Antiepileptic Therapy: Advances in Drug Monitoring. New York, Raven Press, 1980, pp 81–86.Google Scholar
  43. 43.
    Aman MG, Werry JS, Paxton JW, et al: Effects of phenytoin on cognitive-motor performance in children as a function of drug concentration, seizure type, and time of medication. Epilepsia 35:172–180, 1994.PubMedCrossRefGoogle Scholar
  44. 44.
    Gallassi R, Morreale A, Lorusso S, et al: Carbamazepin and phenytoin: Comparison of cognitive effects in epileptic patients during monotherapy and withdrawal. Arch Neurol 45:892–894, 1988.PubMedCrossRefGoogle Scholar
  45. 45.
    Dodrill CB, Temkin NR: Motor speed is a contaminating factor in evaluating the “cognitive” effects of phenytoin. Epilepsia 30:453–457, 1989.PubMedCrossRefGoogle Scholar
  46. 46.
    Meador KJ, Loring DW, Huh K, et al: Comparative cognitive effects of anticonvulsants. Neurology 40: 391–394, 1990.PubMedCrossRefGoogle Scholar
  47. 47.
    Meador KJ, Loring DW, Allen ME, et al: Comparative cognitive effects of carbamazepine and phenytoin in healthy adults. Neurology 41:1537–1540, 1991.PubMedCrossRefGoogle Scholar
  48. 48.
    Dalby MA: Behavioral effects of carbamazepine, in Penry JK, Daly DD (eds): Advances in Neurology. New York, Raven Press, 1975, pp 331–343.Google Scholar
  49. 49.
    Mattson RH. Selection of antiepileptic drug therapy, in Levy R, Mattson R, Meldrum B, et al (eds): Antiepileptic Drugs, ed 3. New York, Raven Press, 1989, pp 103–115.Google Scholar
  50. 50.
    Silverstein FS, Parrish MA, Johnston MV: Adverse behavioral reactions in children treated with carbamazepine (Tegretol). J Pediatr 101:785–787, 1982.PubMedCrossRefGoogle Scholar
  51. 51.
    Verity CM, Hosking G, Easter DJ: A multicentre comparative trial of sodium valproate and carbamazepine in paediatric epilepsy. Dev Med Child Neurol 37:97–108, 1995.PubMedCrossRefGoogle Scholar
  52. 52.
    O’Dougherty M, Wright FS, Cox S, et al: Carbamazepine plasma concentration: Relationship to cognitive impairment. Arch Neurol 44:863–867, 1987.PubMedCrossRefGoogle Scholar
  53. 53.
    Aman MG, Werry JS, Paxton JW, et al: Effects of carbamazepine on psychomotor performance in children as a function of drug concentration, seizure type, and time of medication. Epilepsia 31:51–60, 1990.PubMedCrossRefGoogle Scholar
  54. 54.
    Aman MG, Werry JS, Paxton JW, et al: Effect of sodium valproate on psychomotor performance in children as a function of dose, fluctuations in concentration, and diagnosis. Epilepsia 28:115–124, 1987.PubMedCrossRefGoogle Scholar
  55. 55.
    Herranz JL, Arteaga R, Armijo JA: Side effects of sodium valproate in monotherapy controlled by plasma levels: A study in 88 pediatric patients. Epilepsia 23:203–214, 1982.PubMedCrossRefGoogle Scholar
  56. 56.
    Pakalnis A, Drake ME, Denio L: Valproate associated encephalopathy. J Epilepsy 2:41–44, 1989.CrossRefGoogle Scholar
  57. 57.
    Browne TR: Clonazepam. Arch Neurol 33:326–332, 1976.PubMedCrossRefGoogle Scholar
  58. 58.
    Bensch J, Blennow G, Ferngren H: A double blind study of clonazepam in the treatment of therapy resistant epilepsy. Dev Med Child Neurol 19:335–342, 1977.PubMedCrossRefGoogle Scholar
  59. 59.
    Ghoneim MM, Mewaldt SP, Berie JL, et al: Memory and performance effects of single and 3 week administration of diazepam. Psychopharmacology 73:147–151, 1981.PubMedCrossRefGoogle Scholar
  60. 60.
    Munn R, Farrell K: Open study of clobazam in refractory epilepsy. Pediatr Neurol 9:465–469, 1993.PubMedCrossRefGoogle Scholar
  61. 61.
    The Felbamate Study Group in Lennox-Gastaut syndrome: Efficacy of felbamate in childhood epileptic encephalopathy. N Engl J Med 328:29–33, 1993.CrossRefGoogle Scholar
  62. 62.
    Wilder BJ. How about the new antiepileptic drugs? Can J Neurol Sei 21(suppl.3):S17-S20, 1994.Google Scholar
  63. 63.
    Leach JP, Girvan J, Paul A, et al: Gabapentin and cognition: A double blind, dose ranging, placebo controlled study in refractory epilepsy. J Neurol Neurosurg Psychiatry 62:372–376, 1997.PubMedCrossRefGoogle Scholar
  64. 64.
    Chadwick D: The role of gabapentin in epilepsy management, in Chadwick D, Browne TR (eds): New Trends in Epilepsy Management. The Role of Gabapentin (Proceedings of a satellite symposium held during Epilepsy Europe 1993). London, N Royal, 1993 pp 59–65.Google Scholar
  65. 65.
    Lee DO, Steingard RJ, Cesena M, et al: Behavioral side effects of gabapentin in children. Epilepsia 37:87–90, 1996.PubMedCrossRefGoogle Scholar
  66. 66.
    Wolf SM, Shinnar S, Kang H, et al: Gabapentin toxicity in children manifesting as behavioral changes. Epilepsia 36:1203–1205, 1996.CrossRefGoogle Scholar
  67. 67.
    Cugley AL, Swartz BE: Gabapentin associated mood changes? Epilepsia 36(suppl. 4):S72, 1995.Google Scholar
  68. 68.
    Schantz D, Towbin JA, Spitz MD: Changes in mood and affect in patients on gabapentin. Epilepsia 36(suppl 4):S73, 1995.Google Scholar
  69. 69.
    Zupanc ML, Schroeder VM: Behavioral changes in children on gabapentin. Epilepsia 36(suppl 4):S73, 1995.Google Scholar
  70. 70.
    Banks GK, Beran RG. Neuropsychological assessment in lamotrigine treated epileptic patients. Clin Exp Neurol 28:230–237, 1991.PubMedGoogle Scholar
  71. 71.
    Besag FM: Lamotrigine: Paediatric experience, in Richens A (ed): Clinical update on Lamotrigine: A Novel Antiepileptic Agent. Kent, England, Wells Medical Ltd, 1992, pp 53–60.Google Scholar
  72. 72.
    Leary PM, Allie S: A new drug suitable for children and young people with epilepsy and intellectual impairments. Epilepsia 34(suppl 6):371, 1995Google Scholar
  73. 73.
    Shorvon SD: Safety of topiramate: Adverse events and relationships to dosing. Epilepsia 37(suppl 2):S18-S22, 1996.CrossRefGoogle Scholar
  74. 74.
    Glauser TA: Preliminary observations on topiramate in pediatric epilepsies, Epilepsia 38(suppl 1):S37-S41, 1997.CrossRefGoogle Scholar
  75. 75.
    Dodrill CB, Arnett JL, Sommerville KW, et al: Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy. Epilepsia 36:64–173, 1995.CrossRefGoogle Scholar
  76. 76.
    Grünewald RA, Thompson PJ, Corcoran R, et al: Effects of vigabatrin on partial seizures and cognitive function. JNeurol Neurosurg Psychiatry 54:1057–1063, 1994.CrossRefGoogle Scholar
  77. 77.
    McGuire AM, Duncan JS, Trimble MR: Effects of vigabatrin on cognitive function and mood when used as add-on therapy in patients with intractable epilepsy. Epilepsia 33:128–134, 1992.PubMedCrossRefGoogle Scholar
  78. 78.
    Provinciali L, Bartolini M, Mari F, et al: Influence of vigabatrin on cognitive performances and behaviour in patients with drug-resistant epilepsy. Acta Neurologica Scand 94:12–18, 1996.CrossRefGoogle Scholar
  79. 79.
    Gillham RA, Blacklaw J, McKee PJW, et al: Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy. J Neurol Neurosurg Psychiatry 56:1271–1275, 1993PubMedCrossRefGoogle Scholar
  80. 80.
    Kalviainen R, Aikia M, Saukkonen AM, et al: Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. Acta Neurol Scand 52:989–996, 1995.Google Scholar
  81. 81.
    Ferrie CD, Robinson RO, Panayiotopoulos CP: Psychotic and severe behavioral reactions with vigabatrin: A review. Acta Neurol Scand 93:1–8, 1996.PubMedCrossRefGoogle Scholar
  82. 82.
    Reynolds EH: 7-Vinyl GABA (vigabatrin): Clinical experience in adult and adolescent patients with intractable epilepsy. Epilepsia 33(suppl 5):S30-S35, 1992.Google Scholar
  83. 83.
    Dodrill CB, Batzel LW: Interictal behavioral features of patients with epilepsy. Epilepsia 27:S64-S76, 1986.CrossRefGoogle Scholar
  84. 84.
    Tunks ER, Dernier SW: Carbamazepine in the dyscontrol syndrome associated with limbic system dysfunction. J Nerv Ment Dis 164:56–63, 1977.PubMedCrossRefGoogle Scholar
  85. 85.
    Kessler AJ, Barklage NE, Jefferson JW: Mood disorders in the psychoneurologic borderland: Three cases of responsiveness to carbamazepine. Am J Psychiatry 146:81–83, 1989.PubMedGoogle Scholar
  86. 86.
    Small JG: Anticonvulsants in affective disorders. Psychopharmacol Bull 26:25–36, 1990.PubMedGoogle Scholar
  87. 87.
    Post RM, Altshuler LL, Ketter TA, et al: Antiepileptic drugs in affective illness. Clinical and theoretical implications. Adv Neurol 55:239–277, 1991.PubMedGoogle Scholar
  88. 88.
    Carpenter WT, Kurz R, Kirkpatrick B, et al: Carbamazepine maintenance treatment in outpatient schizophrenics. Arch Gen Psychiatry 48:69–72, 1991.PubMedCrossRefGoogle Scholar
  89. 89.
    Neppe VM: Carbamazepine in nonresponsive psychosis. J Clin Psychiatry 49:22–28, 1988.PubMedGoogle Scholar
  90. 90.
    Young JL, Hillbrand M: Carbamazepine lowers aggression: A review. Am Acad Psychiatry Law 22:53–61, 1994.Google Scholar
  91. 91.
    Remschmidt H: The psychotropic effects of carbamazepine in non epileptic patients, with particular reference to problems posed by clinical studies in children with behavioural disorders, in Birkmayer W (ed): Epileptic Seizures—Behaviour—Pain. Bern, Hans Huber, 1976, pp 253–258.Google Scholar
  92. 92.
    Evans RW, Clay TH, Gualtieri CT: Carbamazepine in pediatric psychiatry. J Am Acad Child Adolesc Psychiatry 26:2–8, 1987.PubMedCrossRefGoogle Scholar
  93. 93.
    Groh C: The psychotropic effect of Tegretol in non epileptic children, with particular reference to the drug’s indications, in Birkmayer W (ed): Epileptic SeizuresBehaviourPain. Bern, Hans Huber, 1976, pp 259–263.Google Scholar
  94. 94.
    Puente RM: The use of carbamazepine in the treatment of behavioural disorders in children, in Birkmayer W (ed): Epileptic Seizures—Behaviour—Pain. Bern, Hans Huber, 1976, pp 243–252.Google Scholar
  95. 95.
    Kuhn-Gebhart V: Behavioural disorders in non epileptic children and their treatment with carbamazepine, in Birkmayer W (ed): Epileptic Seizures—Behaviour—Pain. Bern, Hans Huber, 1976, pp 264–267.Google Scholar
  96. 96.
    McElroy SL, Keck PE, Harrison GP, et al: Valproate in psychiatric disorders: Literature review and clinical guidelines. J Clin Psychiatry 50(suppl 3):23–29, 1989.PubMedGoogle Scholar
  97. 97.
    Trimble MR: Anticonvulsants in children and adolescents. J Child Adolesc Psychopharmacol 1:107–124, 1990.PubMedCrossRefGoogle Scholar
  98. 98.
    Mitchell WG, Chavez JM: Carbamazepine versus phenobarbital for partial onset seizures in children. Epilepsia 28:56–60, 1987.PubMedCrossRefGoogle Scholar
  99. 99.
    Duncan JS, Shorron SD, Trimble MR: Effects of removal of phenytoin, carbamazepine, and valproate on cognitive function. Epilepsia 31:584–591, 1990.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • Eileen P. G. Vining
    • 1
  • Richard O. Carpenter
    • 2
  • Michael G. Aman
    • 3
  1. 1.Department of Neurology and PediatricsJohns Hopkins University School of MedicineBaltimoreUSA
  2. 2.Private practiceAtlantaUSA
  3. 3.The Nisonger Center for Mental Retardation and Developmental DisabilitiesOhio State UniversityColumbusUSA

Personalised recommendations